Roche
AI overview
Sign in and the AI will write an overview from our coverage.
Headlines · 2
- Simcere president takes IT department under direct control, mandates AI use
36Kr reports that Simcere Pharmaceutical president Zhou Yunshu brought the company's information department under his direct management in 2026 and said at a recent media briefing that managers are required, not merely encouraged, to embrace AI in their work. The company embedded AI engineers into business units so that AI could gradually move from an auxiliary tool to a basic function across target discovery, clinical work, drug manufacturing, marketing and operations, and in July 2026 Simcere signed a drug discovery and development collaboration with US AI drug discovery company Schrödinger. The report also notes that for pharma companies without an AI-native background, measuring AI's actual value remains difficult, and that Simcere spent a large number of tokens on early exploration.
36氪 人工智能 · 🔥 0 - Roche says AI informs 40% of pipeline decisions, targets 80%
At its late-September Pharma Day investor event, Roche said 40% of pipeline decisions from Q4 2025 to Q2 2026 carried a traceable AI or computational contribution, rising to 44% in Q2 2026, split 41% critical, 48% supportive and 10% informational. Genentech gRED head Aviv Regev presented the target-evaluation agent TargetNexus and a "Lab-in-the-Loop" system aiming to be involved in 80% of research portfolio decisions by Q4 this year. Roche says that with nominally flat resources and lead-identification cycles halved, projects entering lead identification rose 155% and internally generated development candidates rose 50% between 2022 and 2025, and one biologics program reached a clinical candidate in 18 months, with first patient dosed this year. Caveats: Roche has not disclosed how it scores AI contributions, 40% times 41% implies only about 16% of decisions were critically AI-influenced, and the Phase III success rise from 65% in 2025 to above 80% cannot be separated from the stricter "The Bar" framework; no approved drug has yet come from the closed loop.
MIT科技评论中文 · 🔥 0
Experience and discussion from the community
Share my Roche experienceAsk about Roche
Nobody has shared their experience with Roche yet.